Does Oscar Health Cover Prolia?

How Oscar Health Classifies Prolia on Its Formulary

Oscar Health plans classify Prolia as a specialty biologic administered by a healthcare provider, which means it falls under the medical benefit rather than the pharmacy benefit for most members. This distinction matters because medical-benefit drugs are billed through the provider and subject to the plan's medical cost-sharing structure, not pharmacy copay tiers.

Oscar's publicly available formularies list denosumab as a covered agent for the treatment of osteoporosis in postmenopausal women at high risk of fracture, glucocorticoid-induced osteoporosis, and bone loss in men receiving androgen deprivation therapy for prostate cancer [1]. These are the same three adult indications the FDA approved between 2010 and 2012. Oscar does not publish a single national formulary. Each state market has its own plan documents, so the exact tier placement and cost-sharing percentage can shift depending on whether a member enrolled through a Silver, Gold, or Bronze marketplace plan.

Because Prolia is injected subcutaneously in a clinical setting every six months, Oscar processes claims under HCPCS code J0897. Members should confirm with their provider's billing office that the claim will be submitted to Oscar's medical benefit side, not the pharmacy side, to avoid unnecessary claim rejections.

Prior Authorization Requirements for Prolia Under Oscar

Oscar Health requires prior authorization before covering Prolia in nearly all cases. The prior authorization process serves as a clinical checkpoint: Oscar's utilization management team reviews whether the member meets specific medical necessity criteria before approving the drug.

Standard criteria that Oscar applies (consistent with guidelines from the American Association of Clinical Endocrinology) include a confirmed diagnosis of osteoporosis via dual-energy X-ray absorptiometry (DXA) showing a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip, or a history of fragility fracture [2]. Oscar also requires documentation that the patient has tried and failed, or has a documented contraindication to, at least one oral bisphosphonate such as alendronate or risedronate. This step-therapy requirement reflects the 2020 Endocrine Society guideline recommendation that bisphosphonates remain first-line for most patients with osteoporosis [3].

Providers submitting the prior authorization request should include the DXA scan results with dates, a list of prior osteoporosis medications with start and stop dates and reasons for discontinuation, and any relevant lab work (serum calcium, 25-hydroxyvitamin D, renal function). Oscar's standard prior authorization review takes up to 5 business days. Urgent requests, such as those for patients with recent vertebral fractures, can be expedited within 72 hours.

What Prolia Costs Oscar Health Members

The out-of-pocket cost of Prolia for an Oscar Health member depends on three variables: plan metal tier, deductible status, and whether the member has reached the annual out-of-pocket maximum.

Prolia's wholesale acquisition cost (WAC) is approximately $1,900 per 60 mg prefilled syringe. For members on Oscar Silver plans who have met their deductible, a typical coinsurance rate of 20% to 30% translates to roughly $380 to $570 per injection before any additional negotiated discounts. Members on Gold plans with lower coinsurance rates (often 10% to 20%) may pay $190 to $380. Bronze plan holders face higher coinsurance, sometimes 40% to 50%, making the per-injection cost $760 to $950 until the out-of-pocket maximum is reached.

Once a member hits the annual out-of-pocket maximum (which ranges from approximately $4,500 to $9,200 on Oscar marketplace plans depending on the tier), Prolia and all other covered services are paid at 100% by Oscar for the remainder of the plan year.

Oscar members who receive Prolia twice annually at $1,900 list price face a total annual drug cost of $3,800 before insurance. For a Silver plan member with a $3,500 deductible and 20% coinsurance, the estimated annual out-of-pocket for Prolia alone could range from $760 to $1,160, depending on how much deductible has been satisfied by other medical expenses earlier in the year.

Step Therapy: Why Oscar Requires a Bisphosphonate Trial First

Step therapy is the most common reason Oscar Health initially restricts access to Prolia. The logic behind this requirement is both clinical and economic. Generic alendronate costs roughly $10 to $30 per month, while Prolia costs approximately $3,800 per year at list price.

From a clinical perspective, the FREEDOM trial (N=7,868) demonstrated that denosumab reduced the risk of new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared to placebo [4]. The Fracture Intervention Trial (FIT) showed that alendronate reduced vertebral fracture risk by 47% over three years [5]. Both drugs are effective, but head-to-head data remain limited.

Oscar's step-therapy protocol typically accepts any of the following as grounds to bypass bisphosphonate requirements:

• Documented esophageal stricture, Barrett's esophagus, or achalasia (contraindications to oral bisphosphonates)
• History of gastrointestinal intolerance (severe GERD, esophagitis) while on an oral bisphosphonate
• Creatinine clearance below 30 to 35 mL/min, which contraindicates bisphosphonates per FDA labeling
• A new fracture that occurred while the patient was adherent to bisphosphonate therapy for 12 or more months
• Inability to remain upright for 30 minutes after dosing (oral bisphosphonate requirement)

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has noted: "For patients who cannot tolerate oral bisphosphonates or who fracture despite adherent therapy, denosumab represents a well-validated second-line option with strong fracture-reduction data" [6].

How to Appeal an Oscar Denial for Prolia

If Oscar Health denies prior authorization for Prolia, members and their providers have the right to appeal. Oscar's appeals process follows Affordable Care Act (ACA) regulations and involves two internal levels and one external review option.

The first-level internal appeal must be filed within 180 days of the denial notice. Providers should submit a letter of medical necessity that directly addresses the specific reason for denial. If Oscar denied coverage because step therapy was not completed, the appeal letter should document why bisphosphonates are contraindicated or have failed. Include chart notes, DXA results, fracture imaging, GI consultation records, or renal function labs as supporting evidence.

If the first-level appeal is denied, a second-level appeal goes to a different set of Oscar medical reviewers. According to data from the Kaiser Family Foundation, marketplace insurers overturn between 40% and 60% of internal appeals for specialty medications when adequate clinical documentation is provided [7].

If both internal appeals fail, members can request an external review through their state's independent review organization (IRO). The external reviewer is a physician not affiliated with Oscar. External review decisions are binding on the insurer. The Centers for Medicare & Medicaid Services (CMS) requires that external reviews for marketplace plans be completed within 45 days for standard requests and 72 hours for expedited requests involving urgent clinical situations [8].

Oscar also offers a concurrent review option: if a member's physician believes the patient's health is in immediate jeopardy without Prolia, an expedited appeal can be filed and must be resolved within 72 hours.

Prolia Coverage for Specific Osteoporosis Indications

Oscar Health's coverage criteria for Prolia vary depending on the specific FDA-approved indication.

Postmenopausal osteoporosis in women at high fracture risk. This is the most common indication and the one with the most straightforward approval pathway. Oscar generally covers Prolia for postmenopausal women with a T-score of <-2.5 or a prior fragility fracture who have failed or cannot take oral bisphosphonates. The FREEDOM extension study followed patients for up to 10 years and showed continued fracture risk reduction and BMD gains with long-term denosumab use, with cumulative lumbar spine BMD increases of 21.7% from baseline [9].

Glucocorticoid-induced osteoporosis (GIOP). Patients taking 7.5 mg or more of prednisone daily for 3 months or longer are at elevated fracture risk. The 2017 American College of Rheumatology guideline conditionally recommends denosumab for adults aged 40 and older on long-term glucocorticoids who cannot take oral bisphosphonates [10]. Oscar covers Prolia for GIOP with documentation of glucocorticoid dose, duration, and bisphosphonate intolerance or failure.

Male osteoporosis and androgen deprivation therapy. Men receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer lose bone density at an accelerated rate. The HALT trial (N=1,468) demonstrated that denosumab increased BMD at the lumbar spine by 5.6% at 24 months compared to placebo in men receiving ADT [11]. Oscar covers Prolia for this indication with documentation of ADT use and DXA-confirmed bone loss.

Alternatives If Oscar Denies or Restricts Prolia

Members who face coverage barriers have several paths to consider.

Amgen Assist and copay programs. Amgen's patient assistance program may cover the full cost of Prolia for uninsured patients or those whose insurance does not cover the drug. Commercially insured patients with out-of-pocket costs may qualify for Amgen's copay card, which can reduce per-injection costs to as low as $0 for eligible patients. ACA marketplace plan members are generally not eligible for manufacturer copay cards under federal anti-kickback statute interpretations, but uninsured patients can apply directly to Amgen Assist.

Biosimilar options. The FDA approved the first Prolia biosimilar, Sandoz's denosumab-bddz (Jubbonti), in 2024. As biosimilar availability expands, Oscar may update formulary placement and potentially reduce step-therapy requirements for biosimilar versions. Biosimilar pricing is expected to be 15% to 30% lower than branded Prolia based on historical biosimilar price reductions across other biologic classes [12].

Intravenous zoledronic acid. Zoledronic acid (Reclast) is given as a once-yearly IV infusion and has strong fracture-reduction data from the HORIZON Key Fracture Trial (N=7,765), which showed a 70% reduction in vertebral fractures and a 41% reduction in hip fractures over three years [13]. Oscar covers zoledronic acid with fewer restrictions than Prolia because a generic version is available at substantially lower cost. For patients with adequate renal function (CrCl above 35 mL/min), zoledronic acid may be a viable covered alternative.

Teriparatide or abaloparatide. For patients with very severe osteoporosis (multiple vertebral fractures, T-score below -3.0), anabolic agents such as teriparatide (Forteo) or abaloparatide (Tymlos) may be appropriate. These drugs build new bone rather than slowing resorption. Oscar typically requires prior authorization for anabolic agents as well, with criteria focused on fracture severity and prior antiresorptive failure.

What Oscar Members Should Do Before Their First Prolia Injection

Before scheduling Prolia, Oscar members should take three concrete steps. First, call the member services number on the back of the Oscar insurance card and ask specifically whether Prolia (HCPCS code J0897) requires prior authorization under the member's current plan. Second, ask the prescribing physician's office to submit the prior authorization request at least 10 business days before the planned injection date to allow time for review and any appeals. Third, request a pre-treatment benefits estimate from the provider's billing department so the expected out-of-pocket cost is clear before the injection.

Members should also confirm that serum calcium and 25-hydroxyvitamin D levels have been checked and corrected before starting Prolia. The Endocrine Society's 2019 clinical practice guideline recommends maintaining 25-hydroxyvitamin D levels above 30 ng/mL and ensuring adequate calcium intake (1,000 to 1 to 200 mg daily) before and during denosumab therapy to minimize the risk of hypocalcemia [14].

Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research & Osteoporosis Center, has stated: "Every patient starting denosumab should have vitamin D sufficiency confirmed and calcium intake optimized. Hypocalcemia is rare but preventable with proper pre-treatment assessment" [15].

Patients who miss a scheduled Prolia dose face a documented risk of rebound vertebral fractures. A 2017 analysis published in the Journal of Clinical Endocrinology & Metabolism found that patients who discontinued denosumab without transitioning to another antiresorptive agent experienced rapid bone loss and a clustering of multiple vertebral fractures in some cases [16]. Oscar members should coordinate with their provider to ensure no gaps in treatment authorization.